Imvax, Inc. has appointed Mark Exley, PhD, as Chief Scientific Officer, reporting to Chief Executive Officer John Furey. Dr. Exley was previously Vice President, Cellular Immunology for AgenTus. He joins the company as Imvax develops its lead product candidate, IGV-001 for the treatment of newly diagnosed glioblastoma multiforme (GBM).

Dr. Exley’s areas of research include natural and vaccine-supported immunity to cancers, immune responses to acute and chronic viral infections, suppression of graft-versus-host disease, obesity-associated diseases and other inflammations. Dr. Exley has published over 120 articles in scientific journals and has received numerous research awards and grants.

Prior to joining Imvax, Dr. Exley was on faculty at Harvard Medical School and at the University of Manchester, UK, where he retains honorary appointments, and was a scientist at Immulogic, Inc. 

“Mark brings a wealth of experience to Imvax in the regulation of the immune system to treat cancer and other diseases,” said Mr. Furey. “He will provide our team with invaluable insights and leadership as we continue to build on the current promise of our early clinical trial work with IGV-001 and execute on the future clinical development of this asset.”